Evidence map›Paper›PMID 40329475›Full record

ArticleJournal of managed care & specialty pharmacy2025

The consequences of pharmaceutical tariffs in the United States.

Sean D Sullivan, Jens Grueger, Aidan P Sullivan, Scott D Ramsey

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sean D SullivanThe CHOICE Institute, School of Pharmacy, University of Washington, Seattle.
Jens GruegerThe CHOICE Institute, School of Pharmacy, University of Washington, Seattle.
Aidan P SullivanDepartment of Data Science, Colorado School of Mines, Golden.
Scott D RamseyFred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Trump Administration has threatened to impose tariffs on imported branded, generic, and biosimilar pharmaceutical products. Although specific details regarding the exact rates and implementation timeline remain unclear, the administration has indicated that these tariffs will be substantial. Tariffs can create supply chain disruptions, increase costs, limit patient access to essential medications, and negatively impact research and innovation. Rather than punitive tariffs, industrial policy options and collaborative international treaties may better serve US economic and public health interests and lead to a more secure and consistent domestic supply of critical medicines.

Indexed as

Drug CostsDrug IndustryBiosimilar PharmaceuticalsDrugs, GenericHumansUnited StatesBiosimilar PharmaceuticalsDrugs, Generic

Identifiers

PMID40329475
PMCPMC12123191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.